Unidentified Analyst: Perfect, thank you. I know you’ve mentioned previously that you’ve had patients come in talking about Renuvion. Are you still seeing that specifically so far early this year?
Charles D. Goodwin: Yes, so the great thing about awareness and a great thing about building on this is, is every day, every week, every year, awareness of the technology becomes more and more. And that word of mouth helps to spread not only from a patient perspective but also from a physician perspective. And so that will be something that will keep building us as we go throughout the years here for sure.
Unidentified Analyst: Great, thank you.
Operator: Thank you. Our next question comes from the line of David Turkaly with Citizens JMP. Please proceed with your question.
David Turkaly: Hey, good morning. Just one quick one. Given all the progress you made with the label, all the sort of expansion you got there. I’m just curious, what are the conversations like with the docs here domestically specifically? I know you mentioned capital challenges, we talked about that. But does it resonate, let’s say, vis-a-vis the competition with these surgeons, are they aware of these labels, are they aware that others don’t have it, is there anything — how often does that come up in conversation, any sort of color you can give us in terms of the benefit from all that work you did?
Charles D. Goodwin: Yes. No, it’s a great question, and I appreciate the question. And yes, it does resonate with doctors. In fact, the frustrating thing is our pipeline has probably never been stronger than it is right now and it’s not a function of doctors saying no or saying they don’t want it or they don’t — they want us to go away. It’s just come back and see me in a little bit. They’re just unsure of what the environment is going to be, and it’s — and they’re unsure to make capital purchases in this time. And we’re seeing it not just here, it’s being seen throughout the industry right now. And that’s really the thing. But yes, it does resonate with doctors. And yes, they are appreciative of that. And not only is it just the clearances that we’ve got but we now have over 92 clinical papers that talk about the safe and effective use of our technology.
And I don’t know if anybody else in what we’re doing that’s got even close to that body of evidence. And so all of that stuff, that evidence-based medicine definitely resonates with plastic surgeons for sure.
David Turkaly: Thank you.
Operator: Thank you. We are currently showing no remaining questions at this time. That does conclude our conference for today. Thank you for your participation.
